|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15281529153015311532153315341535153615371538...15771578» |
- || CC-115 / BMS
Enrollment change, Trial initiation date, Trial primary completion date, Metastases: Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. (clinicaltrials.gov) - Nov 15, 2015
P1a/1b, N=144, Active, not recruiting, Sponsor: Celgene Corporation
N=75 --> 144 | Initiation date: Oct 2011 --> Apr 2011 | Trial primary completion date: Feb 2016 --> Oct 2014
- Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Nov 15, 2015
P2, N=7, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=75 --> 144 | Initiation date: Oct 2011 --> Apr 2011 | Trial primary completion date: Feb 2016 --> Oct 2014 Recruiting --> Active, not recruiting | N=78 --> 7 | Trial primary completion date: May 2016 --> Jan 2014
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma (clinicaltrials.gov) - Nov 15, 2015
P3, N=106, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=78 --> 7 | Trial primary completion date: May 2016 --> Jan 2014 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2015
- p53MVA - Tara I / O
Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Nov 14, 2015
P1, N=12, Recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2015 Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016
- ||||| Tazverik (tazemetostat) / Ipsen
New P2 trial: A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 14, 2015
P2, N=90, Not yet recruiting, Sponsor: Epizyme, Inc.
- | Tazverik (tazemetostat) / Ipsen
New P1 trial: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma (clinicaltrials.gov) - Nov 14, 2015
P1, N=44, Not yet recruiting, Sponsor: Epizyme, Inc.
- veliparib (ABT-888) / AbbVie, Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, PARP Biomarker: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Nov 11, 2015
P1, N=474, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Nov 2015 | Trial primary completion date: May 2017 --> Nov 2016 N=96 --> 474
- | Votrient (pazopanib) / Novartis, BeiGene, sapanisertib (CB-228) / Calithera
New P2 trial, Metastases: Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 11, 2015
P2, N=134, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || letrozole / Generic mfg.
Trial primary completion date: Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma (clinicaltrials.gov) - Nov 10, 2015
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=96 --> 474 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial primary completion date: 124I-FIAU Imaging in EBV and KSHV Associated Cancers (clinicaltrials.gov) - Nov 10, 2015
P0, N=15, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- AU-101 / Aurora Biopharma
Trial primary completion date, Metastases: Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (clinicaltrials.gov) - Nov 10, 2015
P1, N=36, Recruiting, Sponsor: Baylor College of Medicine
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jul 2015 --> Jul 2016
- || Trial primary completion date: US-nCLE: Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract (clinicaltrials.gov) - Nov 10, 2015
P=N/A, N=70, Recruiting, Sponsor: Mauna Kea Technologies
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Nov 2014 --> Sep 2016
- | dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment change, Trial primary completion date: Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) - Nov 10, 2015
P2, N=33, Active, not recruiting, Sponsor: Manmeet Ahluwalia, MD
Trial primary completion date: Nov 2014 --> Sep 2016 N=55 --> 33 | Trial primary completion date: Dec 2014 --> May 2016
- Enrollment change: Development of Serologic Assays for Human Herpes Virus-8 (clinicaltrials.gov) - Nov 9, 2015
P=N/A, N=429, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
N=55 --> 33 | Trial primary completion date: Dec 2014 --> May 2016 N=100 --> 429
- Votrient (pazopanib) / Novartis, BeiGene
Trial primary completion date, Combination therapy: Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=5, Terminated, Sponsor: Memorial Sloan Kettering Cancer Center
N=100 --> 429 Trial primary completion date: Nov 2014 --> Nov 2015
- temozolomide / Generic mfg., sorafenib / Generic mfg.
Phase classification: Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Nov 9, 2015
P1, N=18, Completed, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Nov 2014 --> Nov 2015 Phase classification: P1/2 --> P1
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Nov 9, 2015
P1/2, N=99, Recruiting, Sponsor: Eisai Limited
Phase classification: P1/2 --> P1 Active, not recruiting --> Recruiting
- p53MVA - Tara I / O
Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (clinicaltrials.gov) - Nov 8, 2015
P1, N=12, Not yet recruiting, Sponsor: City of Hope Medical Center
Active, not recruiting --> Recruiting Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Oct 2016 --> May 2017
- temozolomide / Generic mfg., sorafenib / Generic mfg.
New P2 trial, P2 data: Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma (clinicaltrials.gov) - Nov 8, 2015
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma (clinicaltrials.gov) - Nov 6, 2015
P1/2, N=99, Active, not recruiting, Sponsor: Eisai Limited
Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Oct 2016 --> May 2017 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, PD(L)-1 Biomarker: Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer (clinicaltrials.gov) - Nov 5, 2015
P1, N=36, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- doxorubicin hydrochloride / Generic mfg.
Trial initiation date, Trial suspension: Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin (clinicaltrials.gov) - Nov 3, 2015
P=N/A, N=150, Suspended, Sponsor: Daniel Rushing
Recruiting --> Active, not recruiting Initiation date: Apr 2015 --> Jan 2016 | Not yet recruiting --> Suspended
- Qinlock (ripretinib) / Ono Pharma
Metastases: A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (clinicaltrials.gov) - Nov 3, 2015
P1, N=50, Recruiting, Sponsor: Deciphera Pharmaceuticals LLC
Initiation date: Apr 2015 --> Jan 2016 | Not yet recruiting --> Suspended Not yet recruiting --> Recruiting
- || Rozlytrek (entrectinib) / Roche
Trial primary completion date, Pan tumor, Metastases: STARTRK-2: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (clinicaltrials.gov) - Nov 1, 2015
P2, N=300, Recruiting, Sponsor: Ignyta, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Oct 2017
- carboplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Nov 1, 2015
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Oct 2015 --> Oct 2016
- | Clinical, Review, Journal: Regulatory network of differentially expressed genes in metastatic osteosarcoma. (Pubmed Central) - Nov 1, 2015
Brain selective kinase2(BRSK2) and aldoketo reductase family1 memberB10(AKRIB10) were present in the screened submodules. The results of the present study suggest that genes, including MMP1, SMO, EWSR1, FEZ1, BRSK2 and AKRIB10, may be potential targets for the diagnosis and treatment of metastatic OS.
- ||| indoximod (NLG8189) / Lumos Pharma
Enrollment change: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors (clinicaltrials.gov) - Oct 30, 2015
P1/2, N=144, Recruiting, Sponsor: NewLink Genetics Corporation
The results of the present study suggest that genes, including MMP1, SMO, EWSR1, FEZ1, BRSK2 and AKRIB10, may be potential targets for the diagnosis and treatment of metastatic OS. N=18 --> 144
- Enrollment closed, Enrollment change, Trial primary completion date: Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation (clinicaltrials.gov) - Oct 30, 2015
P2, N=12, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=18 --> 144 Recruiting --> Active, not recruiting | N=18 --> 12 | Trial primary completion date: Jan 2018 --> Apr 2015
- | lenalidomide / Generic mfg.
Enrollment open: A Study of Lenalidomide for Adult Histiocyte Disorders (clinicaltrials.gov) - Oct 30, 2015
P2, N=12, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=18 --> 12 | Trial primary completion date: Jan 2018 --> Apr 2015 Not yet recruiting --> Recruiting
- Istodax (romidepsin) / Astellas, BMS
Clinical: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction (clinicaltrials.gov) - Oct 28, 2015
P1, N=132, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Sep 2017
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Trial termination, Metastases: Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS (clinicaltrials.gov) - Oct 27, 2015
P2, N=115, Terminated, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Trial primary completion date: Sep 2015 --> Sep 2017 N=182 --> 115 | Recruiting --> Terminated; Interim analysis did not show good results for main objective
- ||| Votrient (pazopanib) / Novartis, BeiGene
Enrollment closed, Enrollment change, Metastases: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial (clinicaltrials.gov) - Oct 27, 2015
P2, N=52, Active, not recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
N=182 --> 115 | Recruiting --> Terminated; Interim analysis did not show good results for main objective Recruiting --> Active, not recruiting | N=74 --> 52
- Tasigna (nilotinib) / Novartis, Inhibikase
New P1/2 trial: GEIS-27: Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum (clinicaltrials.gov) - Oct 27, 2015
P1/2, N=40, Recruiting, Sponsor: Broto, Javier Mart
- Trial primary completion date: A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=9, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting | N=74 --> 52 Trial primary completion date: Jan 2016 --> Jul 2016
- Trial primary completion date: Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer (clinicaltrials.gov) - Oct 27, 2015
P=N/A, N=90, Recruiting, Sponsor: Roswell Park Cancer Institute
Trial primary completion date: Jan 2016 --> Jul 2016 Trial primary completion date: Apr 2017 --> Apr 2018
- Avastin (bevacizumab) / Roche
Trial primary completion date: NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Oct 23, 2015
P2, N=40, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Apr 2017 --> Apr 2018 Trial primary completion date: Oct 2015 --> Apr 2016
- Kisqali (ribociclib) / Novartis
New P2 trial, P2 data, Metastases: A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma (clinicaltrials.gov) - Oct 23, 2015
P2, N=30, Not yet recruiting, Sponsor: Hadassah Medical Organization
- New P1/2 trial: Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors (clinicaltrials.gov) - Oct 23, 2015
P1/2, N=25, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- | camsirubicin (MNPR-201) / Monopar Therap
Enrollment closed, Enrollment change: Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 23, 2015
P2, N=22, Active, not recruiting, Sponsor: Gem Pharmaceuticals
Trial primary completion date: Oct 2015 --> Apr 2016 Recruiting --> Active, not recruiting | N=30 --> 22
- evofosfamide (IMGS-101) / Molecular Templates, ImmunoGenesis
Trial primary completion date, Combination therapy, Metastases: EMR200592-008: A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=46, Recruiting, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting | N=30 --> 22 Trial primary completion date: Oct 2016 --> Jan 2017
- Actimmune (interferon gamma-1 b) / Clinigen, Amgen
Trial primary completion date, IO biomarker: Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=12, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Oct 2016 --> Jan 2017 Trial primary completion date: Oct 2015 --> Apr 2016
- || Piqray (alpelisib) / Novartis
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Oct 22, 2015
P1, N=55, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Jul 2015 --> Dec 2015
- || buparlisib (AN2025) / Novartis, Adlai Nortye
Trial primary completion date, Combination therapy, Stroma: A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients (clinicaltrials.gov) - Oct 22, 2015
P1, N=60, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Apr 2015 --> Dec 2015
- Recentin (cediranib) / AstraZeneca
Trial primary completion date: Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov) - Oct 22, 2015
P2, N=283, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Jan 2015 --> Oct 2015
- Caprelsa (vandetanib) / Sanofi
Trial primary completion date, Combination therapy: A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas (clinicaltrials.gov) - Oct 22, 2015
P2, N=112, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2015 --> Oct 2015 Trial primary completion date: Jan 2016 --> Jun 2015
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial primary completion date: Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov) - Oct 22, 2015
P3, N=416, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jan 2016 --> Jun 2015 Trial primary completion date: Sep 2014 --> Dec 2015
- lexatumumab (ETR2-ST01) / GSK
Trial termination, IO biomarker: HGS-ETR2 to Treat Children With Solid Tumors (clinicaltrials.gov) - Oct 22, 2015
P1, N=19, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2014 --> Dec 2015 Completed --> Terminated
- | amcasertib (BBI-503) / Sumitomo Pharma
Trial initiation date, Trial primary completion date, Stroma, Metastases: A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors (clinicaltrials.gov) - Oct 22, 2015
P2, N=30, Not yet recruiting, Sponsor: Boston Biomedical, Inc
Completed --> Terminated Initiation date: Jan 2015 --> Jul 2016 | Trial primary completion date: Jan 2016 --> Jul 2017
- celecoxib oral / Generic mfg.
Enrollment change, Metastases: Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
Initiation date: Jan 2015 --> Jul 2016 | Trial primary completion date: Jan 2016 --> Jul 2017 N=296 --> 0
- ||||| depatuxizumab mafodotin (ABT-414) / AbbVie
New P2 trial: Intellance1: A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (clinicaltrials.gov) - Oct 22, 2015
P2, N=720, Recruiting, Sponsor: AbbVie